OpenResearchAlpha

Medicine · 13 Nov 2026

Efficacy and safety of fexuprazan versus esomeprazole for healing of endoscopic submucosal dissection-induced artificial gastric ulcers: A multicenter, randomized, open-label, active-controlled trial

Geom Seog Seoh-index 4, Seung Young Seo, Jin Woong Choh-index 5

0
Citations
no database records one yet
0
Citations in 2026
so far
5
Leading author's h-index
Jin Woong Cho, in QAI's scholar index
21
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Background: Endoscopic submucosal dissection (ESD) is a standard treatment for gastric neoplasms but creates artificial ulcers requiring potent acid suppression. Potassium-competitive acid blockers (P-CABs) provide rapid and sustained acid suppression. This study compared the efficacy and safety of fexuprazan, a novel P-CAB, with esomeprazole for the healing of artificial gastric ulcers after ESD. Methods: This multicenter, randomized, open-label, active-controlled trial enrolled patients who underwent gastric ESD. Patients were randomly assigned (1:1) to receive either fexuprazan 40 mg or esomeprazole 40 mg once daily for 8 weeks. The primary endpoint was the ulcer healing rate at 8 weeks. Secondary endpoints included the incidence of delayed bleeding and adverse events. Results: Of 105 randomized patients, 90 were included in the full analysis set (FAS) and 85 in the per-protocol set (PPS). At 8 weeks, the complete healing rate (scar stage) in the PPS was 92.68% (38/41) in the fexuprazan group and 95.45% (42/44) in the esomeprazole group (95% confidence interval: 80.08–98.46 vs 84.53–99.44, P = .67), with an absolute difference of −2.77 percentage points (95% confidence interval: −15.32–8.85). Results were consistent in the FAS (93.02% vs 95.74%, 95% confidence interval: 80.94–98.54 vs 85.46–99.48, P = .67), with an absolute difference of −2.72 percentage points (95% confidence interval: −14.75–8.27). At 8 weeks, no patients in either group remained in the active stage. No delayed bleeding occurred in either group. Treatment-emergent adverse events were minimal and similar between groups (2.00% vs 4.08%, P > .62), with no serious adverse events. Conclusion: Fexuprazan 40 mg once daily showed no statistically significant difference from esomeprazole 40 mg for healing ESD-induced artificial gastric ulcers, with a favorable safety profile. These findings indicate that fexuprazan serves as a reasonable candidate for further investigation as a potential treatment option to proton pump inhibitors for post-ESD ulcer healing.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Jin Woong Cho has the highest h-index among the authors (5).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (3)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (21)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 1 more reference

A free account opens the rest of the citing papers and references on every paper’s page.

Efficacy and safety of fexuprazan versus esomeprazole for healing of endoscopic submucosal dissection-induced artificial gastric ulcers: A multicenter, randomized, open-label, active-controlled trial - QAI OpenResearch